What the review reports
A narrative review in Materials, published 12 June 2026, takes stock of enamel remineralizing agents: their mechanisms of action and their clinical applications, with emphasis on materials used in preventive and minimally invasive dentistry. The framing fact is that dental caries remains the most prevalent chronic disease worldwide, and that early enamel lesions are reversible if managed with appropriate agents. The review’s core assessment: traditional fluoride-based approaches enhance remineralization through fluorapatite formation, but their effectiveness is limited when calcium and phosphate bioavailability is insufficient. Biomimetic agents are presented as the direction addressing that limitation, though the abstract cuts off before detailing which ones and with what evidence.
Why this site tracks remineralisation at all
Thirdteeth covers tooth regeneration, and enamel remineralisation is not regeneration. It is the repair of mineral loss in enamel that already exists, in a tooth that is still alive and in place. We track it for two reasons. First, it is the most evidence-backed form of “regrowing tooth tissue” that actually reaches patients, and it sets the benchmark the speculative routes are implicitly compared against. Second, remineralisation claims are the most common vehicle for hype about regrowing teeth, so the state of the art needs to be on the record in its real form.
Where the evidence sits
A narrative review maps to no single rung of the ladder at /method/; it aggregates other people’s tiers. The strongest claim in the abstract, that fluoride enhances remineralization via fluorapatite, is backed by decades of clinical use and would sit at T5 if this site tiered it. The limitation the review names is equally important and less often repeated: fluoride cannot rebuild mineral when the local supply of calcium and phosphate is inadequate. That is a boundary condition on the most established therapy in dentistry, and it is precisely the gap biomimetic agents are proposed to fill. Whether they do fill it, at human efficacy level, is not something this abstract reports.
Where we differ from the coverage
Consumer coverage routinely collapses three different things into “regrows enamel”: slowing demineralisation, redepositing mineral into a softened early lesion, and rebuilding lost enamel structure. The review supports the first two for established agents in early lesions. Nothing in the abstract supports the third. An early lesion that is reversed was never a cavity, and enamel that has cavitated does not come back from a toothpaste or varnish, whatever the mechanism. That distinction, unglamorous as it is, is the difference between preventive dentistry and regeneration.
What this changes for the record
No tracked programme moves; remineralisation is outside the five routes and the T1 to T5 ladder for regeneration. The entry’s function at /ledger/ is reference: as of June 2026, the published state of the art is fluoride with a named bioavailability limitation, and biomimetic agents as an active but unsettled direction. Any product claiming more than that should be checked against this baseline.
Provenance: every claim above traces to the review’s abstract, per our method at /method/.